Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug
TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged
between 18-65, non-smokers . The study will also look at the nature and quantity of
inflammatory white cells in the lung secretions and in the blood, and some additional
inflammation markers.